<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Ther</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Ther</journal-id><journal-title-group><journal-title>Diabetes Therapy</journal-title></journal-title-group><issn pub-type="ppub">1869-6953</issn><issn pub-type="epub">1869-6961</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26438106</article-id><article-id pub-id-type="pmc">4674468</article-id><article-id pub-id-type="publisher-id">132</article-id><article-id pub-id-type="doi">10.1007/s13300-015-0132-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fu</surname><given-names>Haoda</given-names></name><address><email>fu_haoda@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Dachuang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Boye</surname><given-names>Kristina S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Curtis</surname><given-names>Bradley</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schuster</surname><given-names>Dara L.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kendall</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ascher-Svanum</surname><given-names>Haya</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>6</volume><issue>4</issue><fpage>651</fpage><lpage>651</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e89" ext-link-type="doi" xlink:href="10.1007/s13300-015-0119-x"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Diabetes Ther (2015) 6:317&#x02013;328 DOI: 10.1007/s13300-015-0119-x</title><p>The authors wish to make corrections to the article.</p><p>The third sentence of the &#x0201c;Patient Disposition and Demographics&#x0201d; subsection within the &#x0201c;Results&#x0201d; section should read:</p><p>&#x0201c;For metformin and sulfonylurea, 72% and 74% of patients also had HbA<sub>1c</sub> assessed at week 52.&#x0201d;</p><p>The third paragraph of the &#x0201c;Predictive Parameters&#x0201d; subsection within the &#x0201c;Results&#x0201d; section should read:</p><p>&#x0201c;The predictive parameters for improvements in HbA<sub>1c</sub> for week 24, based on the composite unified early-response measure (reduction in HbA<sub>1c</sub> level of &#x02265;1.0% or HbA<sub>1c</sub> level of &#x0003c;7.0%) for metformin were 0.83, 0.81, 0.44, and 0.96; for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and for insulin glargine, 0.67, 0.89, 0.65, and 0.90.&#x0201d;</p><p>Within the footnote to Table&#x000a0;5, the optimal early-response measure should be defined as:</p><p>&#x0201c;HbA<sub>1c</sub> reduction of &#x02265;1.0% for sulfonylurea and glargine at week 24 and for sulfonylurea at week 52, HbA<sub>1c</sub> reduction of &#x02265;0.8% for metformin at week 24, and HbA<sub>1c</sub> reduction of &#x02265;0.6% for metformin at week 52&#x0201d;.
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s13300-015-0119-x.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></ack></back></article>